Singapore Clinical Trial: A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor

Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant V... Read More

Singapore Clinical Trial: A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease

Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway ... Read More

Singapore Clinical Trial: MK-5684-015: A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'MK-5684-015: A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Select... Read More

Singapore Clinical Trial: CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety... Read More

Singapore Clinical Trial: A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu] Lu-DFC413 and safety and imaging properties of [68Ga] Ga-NNS309 in patients with solid tumors

Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preli... Read More

Singapore Clinical Trial: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart C... Read More

Singapore Clinical Trial: A Single-Arm, Phase IIIb Global, Multi-center Study of Durvalumab in Combination with Tremelimumab and Lenvatinib Given Concurrently with Locoregional Therapy in Participants with Locoregional Hepatocellular Carcinoma (EMERALD-CURE)

Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A Single-Arm, Phase IIIb Global, Multi-center Study of Durvalumab in Combination with Tremelimumab ... Read More

Singapore Clinical Trial: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durv... Read More

Was Tom Hardy fired from MobLand? New report claims actor is still in talks with makers

India, May 29 -- Actor Tom Hardy's reported fallout with the makers of MobLand has become the latest talking point in Hollywood, with recent rumours claiming that the actor had been fired from the cri... Read More

Tirthapati Institution dominates 51st All India Invitation School Rowing Meet

Kolkata/IBNS, May 29 -- City based Tirthapati Institution dominated the proceedings in the junior boys department entering the finals of double scull and fours at the 51st All India Invitation Inter S... Read More

• ««
• «
• 10096
• 10097
• 10098
• 10099
• 10100
• 10101
• 10102
• 10103
• 10104
• 10105
• »
• »»